Moderna (MRNA) isn't planning to invest in new late-stage vaccine trials due to growing opposition to vaccines from US officials, Bloomberg reported Thursday, citing Chief Executive Stephane Bancel.
"You cannot make a return on investment if you don't have access to the US market," Bancel said in an interview with Bloomberg TV at the World Economic Forum in Davos, Switzerland.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: 53.55, Change: +3.74, Percent Change: +7.51
Comments